News
ALNY
330.34
+3.60%
11.49
How New Vutrisiran Outcomes and Zilebesiran Safety Data Will Impact Alnylam Pharmaceuticals (ALNY) Investors
Simply Wall St · 11h ago
BioCryst names Sandeep Menon chief research and development officer
Reuters · 23h ago
Weekly Report: what happened at ALNY last week (0330-0403)?
Weekly Report · 23h ago
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Data And Partnerships At ACC.26
Simply Wall St · 4d ago
Trump may impose tariffs on drugmakers who haven't signed MFN deals - reports
Seeking Alpha · 4d ago
Alnylam Pharma (ALNY) Gets a Buy from Barclays
TipRanks · 6d ago
Alnylam Data Update Highlights RNAi Potential And Undervalued Share Price
Simply Wall St · 6d ago
Genmab names Margarida Duarte general manager for Europe and emerging markets
Reuters · 6d ago
Alnylam’s DemonsTTRate Study: Real-World Data Could Shift the ATTR-CM Investment Story
TipRanks · 6d ago
Piper Sandler Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
TipRanks · 6d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 6d ago
Alnylam presents new data on vutrisiran in ATTR-CM at ACC.26
TipRanks · 03/30 17:11
Alnylam presents new data on potential of zilebesiran for hypertension
TipRanks · 03/30 17:10
Alnylam Presents New Clinical, Real-World Data From Cardiovascular Portfolio At ACC.26, Reinforcing Potential Of RNAi To Deliver Fundamentally Differentiated, Effective, And Durable Impact For Patients Living With CVD
Benzinga · 03/30 17:03
Alnylam’s zilebesiran Phase 2 safety data backs ongoing Phase 3 ZENITH hypertension trial
Reuters · 03/30 17:00
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
Barchart · 03/30 12:00
Alnylam Pharmaceuticals: Solid TTR Demand but Near‑Term Headwinds Justify Hold Rating
TipRanks · 03/30 10:27
Weekly Report: what happened at ALNY last week (0323-0327)?
Weekly Report · 03/30 10:13
AI-Enabled ATTR-CM Care Pathway Initiative Might Change The Case For Investing In Alnylam Pharmaceuticals (ALNY)
Simply Wall St · 03/30 05:06
Analysts Conflicted on These Healthcare Names: Vertex Pharmaceuticals (VRTX), Pacira Pharmaceuticals (PCRX) and Alnylam Pharma (ALNY)
TipRanks · 03/26 07:40
More
Webull provides a variety of real-time ALNY stock news. You can receive the latest news about Alnylam Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.